Arcus Biosciences RCUS Income Statement
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| $17M-48.5% | $33M+26.9% | $26M-83.8% | $160M+471% | $28M+7.7% | ||
| $122M+0.8% | $121M-14.2% | $141M+1.4% | $139M+13.9% | $122M+20.8% | ||
| $29M+11.5% | $26M-3.7% | $27M-6.9% | $29M+3.6% | $28M0.0% | ||
| $151M+2.7% | $147M-12.5% | $168M0.0% | $168M+12.0% | $150M+16.3% | ||
| -$134M-17.5% | -$114M+19.7% | -$142M-1,675% | -$8M+93.4% | -$122M-18.4% | ||
| -788.2%-443pp | -345.5%+201pp | -546.2%-541pp | -5%+431pp | -435.7%-39.6pp | ||
| $3M+50.0% | $2M-33.3% | $3M+50.0% | $2M+100% | $1M-50.0% | ||
| $6M-25.0% | $8M+14.3% | $7M-12.5% | $8M-20.0% | $10M0.0% | ||
| -$128M-20.8% | -$106M+21.5% | -$135M— | $0+100% | -$112M-20.4% | ||
| $0— | $0— | $0— | $0— | $0-100% | ||
| -$128M-20.8% | -$106M+21.5% | -$135M— | $0+100% | -$112M-19.1% | ||
| -752.9%-432pp | -321.2%+198pp | -519.2%-519pp | 0%+400pp | -400%-38.5pp | ||
| -$1.02-13.3% | -$0.90+29.1% | -$1.27— | $0.00+100% | -$1.14-10.7% | ||
| -$132M-18.9% | -$111M+20.7% | -$140M-2,233% | -$6M+95.0% | -$119M-19.0% | ||
| -776.5%-440pp | -336.4%+202pp | -538.5%-535pp | -3.8%+421pp | -425%-40.4pp | ||
| -$134M-17.5% | -$114M+19.7% | -$142M-1,675% | -$8M+93.4% | -$122M-18.4% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- Where does Arcus Biosciences's income statement data come from?
- Every line is extracted from Arcus Biosciences's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.